Paper Details

  1. Home
  2. Paper Details

Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial.

Author: AvarelloJahn, FathiReza, HahnBarry, HouseStacey L, KalfusIra N, LovatoLuis M, MeltzerAndrew C, MillerJoseph B, PlasseTerry F, RadayGilead, SilvermanRobert A, YanEric C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Vomiting from gastroenteritis (stomach flu) is often treated with anti-nausea medications given through a vein. If effective oral treatments were available, people might not need intravenous fluids or medications. Additionally, a long-lasting oral medication could provide longer relief from nausea and vomiting.
Paper Details　
Original Abstract of the Article :
Vomiting resulting from acute gastroenteritis is commonly treated with intravenous antiemetics in acute care settings. If oral treatment were beneficial, patients might not need intravenous administered hydration or medication. Furthermore, a long-acting treatment could provide sustained relief from...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902785/

データ提供：米国国立医学図書館（NLM）

Bimodal Release Ondansetron: A Potential Game-Changer for Acute Gastroenteritis

The management of [acute gastroenteritis (AGE)] often involves intravenous antiemetics, particularly in acute care settings. This research explores the potential of a novel oral antiemetic, bimodal release ondansetron, for the treatment of vomiting associated with AGE. The authors conduct a randomized clinical trial, comparing the efficacy of bimodal release ondansetron to standard intravenous antiemetic treatments. The findings of this study shed light on the potential for oral antiemetics to provide sustained relief from nausea and vomiting in patients with AGE.

Oral Antiemetics: A Viable Alternative for AGE

The study provides compelling evidence for the efficacy of bimodal release ondansetron in treating vomiting associated with AGE. This discovery, like a camel discovering a new oasis, challenges conventional treatment approaches for AGE, suggesting a potential shift towards oral antiemetic therapy. The findings highlight the potential benefits of a long-acting oral antiemetic, potentially reducing the need for intravenous hydration and medication.

Optimizing AGE Management: A More Patient-Centric Approach

The research underscores the potential for oral antiemetics to provide a more patient-centric approach to managing AGE. This shift towards oral treatment could enhance patient comfort and convenience, reducing the need for intravenous interventions. This study serves as a catalyst for exploring the potential of novel oral antiemetics in managing AGE.

Dr.Camel's Conclusion

This study offers a new perspective on the treatment of AGE, highlighting the potential of oral antiemetics. Like a camel navigating the desert, healthcare providers are constantly seeking innovative approaches to improve patient care. This research provides valuable insights into the potential of bimodal release ondansetron, suggesting a more convenient and effective treatment option for AGE.

Date :
  1. Date Completed 2020-06-16
  2. Date Revised 2020-06-16
Further Info :

Pubmed ID

31702802

DOI: Digital Object Identifier

PMC6902785

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.